Results 81 to 90 of about 1,617 (165)

Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis

Frontiers in Public Health
BackgroundRespiratory syncytial virus (RSV) causes lower respiratory tract infections (LRTIs) in infants, leading to substantial morbidity and mortality. Nirsevimab, a long-lasting monoclonal antibody, has been demonstrated to reduce RSV-related outcomes
Samira Soudani, Lorenzo Bertizzolo, Mehdi Ghemmouri, Mary Chappell, Rachael McCool, Katie Reddish, Paul Miller, Erin Barker, Harriet Fewster   +8 more
doaj   +1 more source

How a major discovery can become a public health failure when used subotptimally: lessons from early nirsevimab implementation

Italian Journal of Pediatrics
Background In this Debate, based on our clinical data from the “pre-nirsevimab” and “first year of nirsevimab implementation” bronchiolitis seasons, we challenge the validity of policy decisions that led to partial immunization coverage of eligible ...
Danilo Buonsenso, Aida Perramon-Malavez, Rosa Morello, Carolina Gentili, Marta Bellorofonte, Antoni Soriano-Arandes   +5 more
doaj   +1 more source

A single-center observational study of nirsevimab for prevention of RSV infection in preterm infants

Frontiers in Pediatrics
ObjectiveThis study aims to evaluate the clinical efficacy of nirsevimab in preventing respiratory syncytial virus (RSV) infection in preterm infants, highlighting its potential to improve neonatal respiratory health.MethodsWe conducted a retrospective ...
Rina Su, Rigonggaowa A, Fang Yao, Yanbin An, Cheng Cai, Lei Yun   +5 more
doaj   +1 more source

Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus

JAMA Network Open
IMPORTANCENirsevimab, a long-acting monoclonal antibody, demonstrated efficacy against respiratory syncytial virus (RSV)–associated lower respiratory tract infections (LRTI) in clinical trials. Postlicensure monitoring is essential to confirm these benefits in clinical settings.OBJECTIVETo estimate the effectiveness of nirsevimab against medically ...
Xu, Hanmeng, Aparicio, Camila, Wats, Aanchal, Araujo, Barbara L., Pitzer, Virginia E., Warren, Joshua L., Shapiro, Eugene D., Niccolai, Linda M., Weinberger, Daniel M., Oliveira, Carlos R.   +9 more
openaire   +2 more sources

The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study

Frontiers in Public Health
IntroductionRespiratory syncytial virus (RSV) infection is one of the main causes of morbidity and mortality from lower respiratory tract infections in children under 5 years of age worldwide.
José Francisco Barbas Del Buey, José Francisco Barbas Del Buey, Jesús Íñigo Martínez, María Ángeles Gutiérrez Rodríguez, Marcos Alonso García, Amaya Sánchez-Gómez, María Dolores Lasheras Carbajo, Susana Jiménez Bueno, María Dolores Esteban Vasallo, María Alejandra López Zambrano, Cristina Calvo Rey, Cristina Calvo Rey, Cristina Calvo Rey, Manuel Sanchez Luna, Manuel Sanchez Luna, Marta Molina Olivas, María Araceli Arce Arnáez   +16 more
doaj   +1 more source

Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants’ First RSV Season in the UK

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) poses a significant health burden on infants, particularly during their first RSV season. Immunoprophylactic strategies, such as the administration of nirsevimab, a long-acting monoclonal antibody, have been
Mersha Chetty, Paul Costello, Benjamin Yarnoff, Robert Musci, Mehdi Ghemmouri   +4 more
doaj   +1 more source

Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case–control study, Spain, 2023/24 season

Eurosurveillance
Background Respiratory syncytial virus (RSV) causes substantial morbidity in infants 
the Nirsevimab Effectiveness Study Collaborators
doaj   +1 more source

Nirsevimab and other strategies for the prevention of RSV infection

Anales de Pediatría (English Edition), 2023
Antonio, Iofrío de Arce, Francisco José, Álvarez García   +1 more
openaire   +2 more sources

Efficacy and safety of a single dose of nirsevimab against respiratory syncytial virus infection in infants: a meta-analysis and time-to-event analysis

Italian Journal of Pediatrics
Respiratory syncytial virus (RSV) is one of the causes of lower respiratory tract infections (LRTIs) and related hospitalizations in neonates and infants.
Mohamed Saad Sayed, Mena Ayman Elgendy, Nada Gamil, Hossam Hassan Abdullah, Alaa Alhwary, Rahma Abdulfattah Ibrahim, Sama Hesham Samir, Nada S. Jibril, Hebatullah Abdulazeem, Mohammed Alsabri   +9 more
doaj   +1 more source

Optimal implementation of an Ontario nirsevimab program for respiratory syncytial virus (RSV) prophylaxis: Recommendations from a provincial RSV expert panel

Human Vaccines & Immunotherapeutics
In June 2024, a group of 12 experts in the respiratory syncytial virus (RSV) field representing a cross-section of healthcare provider types who treat and care for pregnant individuals and infants, assembled to discuss the implementation of a broad ...
Bosco Paes, Vivien Brown, Erin Courtney, Erin Fleischer, Fiona Guy, Eddy Lau, Allan Mills, Julie Toole, Meagan Bardan, Cynthia Wong, Gary Lam, Graeme N. Smith   +11 more
doaj   +1 more source